M42 Reveals Advisory Board Of Health And Tech Experts To Innovate Global Health

M42, a pioneering tech-enabled global health entity, recently announced the formation of its new Advisory Board, aimed at revolutionizing the global health sector through advanced personalized, preventive, and precision technology. This board is composed of internationally renowned experts in health and technology, focusing on personal remote care, pharmaceuticals, tech, and longevity. Their mission is to propel M42's vision of crafting a sustainable future for health by fostering collaborations with global industry leaders. This initiative underscores M42's commitment to integrating traditional healthcare provisions with modern health-tech solutions, emphasizing preventive health measures.

Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer of M42, expressed his enthusiasm about the journey ahead. He highlighted the importance of collaboration in disrupting the traditional healthcare industry and emphasized the Advisory Board's role in co-designing the future of health. According to Al Nowais, this future prioritizes individuals' overall well-being over mere healthcare services and focuses on prevention rather than just treatment. The Advisory Board is set to play a crucial role in providing strategic direction, offering insights into emerging trends and technologies, and integrating environmental responsibility with health excellence.

The M42 Advisory Board is tasked with guiding the company towards enhancing patient experiences globally through the use of advanced technologies. It aims to proactively address and prevent health issues by building strategic partnerships that leverage complementary strengths and resources. This collaborative approach is designed to drive innovation, expand market reach, and create shared value for all stakeholders involved.

The Advisory Board boasts an impressive lineup of members from diverse fields, each bringing a unique set of experiences and expertise to the table:

• Dr. David Rhew, Global Chief Medical Officer at Microsoft.
• Professor Sir Chris Evans, Chief Executive Officer of Ellipses Pharma.
• David Sinclair, A.O., Ph.D., Professor of Genetics at Harvard Medical School.
• Dr. James Mault, Chief Executive Officer of BioIntelliSense.

This diverse group is expected to leverage their collective knowledge to drive M42's innovation forward, positioning the company as a leader in the global health sector. By focusing on preventive health solutions and embracing a holistic approach to health, M42 aims to make a significant impact on how healthcare is delivered worldwide.

In conclusion, M42's establishment of its Advisory Board marks a significant step towards transforming the global health landscape. With its focus on collaboration, innovation, and excellence in health-tech, M42 is well-positioned to lead the way in creating a healthier future for people across the globe.

With inputs from WAM